Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News on Pharma

Lilly Sues US Agency For Blocking Proposed Drug Rebate Plan

Eli Lilly is taking the HRSA to court for allegedly blocking the pharma's discount plan.

International Business Times

FDA Implements New Rules For Drug Advertisements

New FDA guidelines enhance transparency in TV drug ads by requiring clearer risk information and neutral presentation of side effects.

Top News

Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

New FDA rules for TV drug ads: Simpler language and no distractions

New rules require drugmakers to be clearer about explaining the risks and side effects of prescription drugs

The Independent UK

Avidity Bio Has Surged 416% This Year — And That's Before Today's 'Game-Changing' News

Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space.

Investors Business Daily

23andMe is laying off 40% of its workforce right before the holiday season

The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile data breach, several rounds of previous layoffs and piling losses that plunged the company’s stock over recent years

The Independent UK

AstraZeneca’s numbers are good but trouble in China could drag it down

Profits beat forecasts but a 17% fall in share price since executives were detained by Beijing may be hard to shake

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

23andMe cuts 40% of its workforce and discontinues therapeutics division

23andMe is laying off 40% of its workforce, or more than 200 employees, and discontinuing its therapeutics division as the struggling genetic testing company attempts to slash costs

The Independent UK

AstraZeneca Reverses As Beat And Raise Outweighs Drug Smuggling Claims

AstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, and AstraZeneca stock rose despite a criminal probe in China.

Investors Business Daily

AstraZeneca says it takes China investigation ‘very seriously’

UK’s biggest pharmaceutical company ‘committed to China’ as it raises 2024 profit forecast and announces $3.5bn US investment

The Guardian - UK

All that You Really want to Be familiar with Arimidex

Arimidex (Anastrozole) is a major area of strength for an inhibitor reliably used to direct estrogen levels in both sensible and lifting loads settings. At first expected to oversee chest most harmful developments in postmenopausal women, Arimidex ...

USA Today Sports Media Group

Cathie Wood Stock Poised To Extend Gains

A Cathie Wood ARK Invest ETF owns over $46 million of this biotech stock. The stock is climbing ahead of its earnings report.

Investors Business Daily

Guardant Health Pops 13% On An 'Impressive' Beat Following Exact Sciences' Flop

Guardant Health stock jumped Thursday on an "impressive" third-quarter report following the launch of its cancer detection test, Shield.

Investors Business Daily

Exact Sciences Collapses On 'Alarming' Guidance Cut. Is The Growth Story Broken?

Exact Sciences stock collapsed Wednesday after the Cologuard maker reported light third-quarter sales and cut its full-year outlook.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Biotech Stocks Edge Higher. Could Trump 2.0 Mean More Innovation, Dealmaking?

Biotech stocks jumped early Wednesday on hopes for more innovation and dealmaking after Donald Trump clinched his second presidency.

International Business Times

Obesity Drug Maker Novo Nordisk Posts Strong Profit

Danish pharmaceutical giant Novo Nordisk, maker of the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy, posted Wednesday strong third-quarter earnings despite being held back by production constraints.

The Guardian - UK

AstraZeneca shares tumble after reports China unit is linked to insurance fraud

Pharmaceutical’s weight loss pill described as ‘underwhelming’, also piling pressure on share price

Kiplinger

Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data

Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.

Get all your
news in one place.

100’s of premium titles.
One news app.

StockNews.com

3 Biotechnology Stocks With Promising Pipelines

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming. Therefore, it could be wise to invest in solid biotech stocks Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD) for substantial returns. Read more.

Investors Business Daily

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH

Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.

Investors Business Daily

ADMA Biologics, A Top 1% Stock, Skyrockets After Settling Its Accounting Debacle

ADMA stock rocketed Friday after the biotech company inked a deal with KPMG as its new independent registered public accounting firm.

The Independent UK

Ozempic, Wegovy considered ‘available’ after more than 2 years in shortage

Demand for the popular weight loss and diabetes drugs has spiked dramatically in recent years

Investors Business Daily

Amgen 'Laser-Focused' On Its Weight-Loss Shot As New Rival Pfizer Follows, Says CFO

Amgen is focusing deeply on its efforts to treat obesity, the CFO said Wednesday. Amgen stock rose early Thursday.

The Street

Eli Lilly stock crushed as weight loss sales, profits, disappoint Wall Street

Eli Lilly's weight loss treatments have powered the company into the top ten list of megacap U.S. stocks.

Kiplinger

Why Pfizer Stock Is Lower After a Beat-and-Raise Quarter

Pfizer stock is down Tuesday even after the drugmaker reported higher-than-expected Q3 earnings and raised its full-year outlook.

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.